TAIGEN BIOTECHNOLIGY CO.,LTD

TAIGEN BIOTECHNOLOGY CO., LTD. is a MANUFACTURER (FACTORY).

Company Introduction:

TAIGEN BIOTECHNOLOGY CO., LTD. is a clinical-stage pharmaceutical company based in Taiwan. Established with a strong emphasis on innovation, the company is dedicated to the research, development, manufacturing, and commercialization of novel therapeutic drugs. Taigen primarily focuses on addressing unmet medical needs, with significant efforts in the fields of anti-infectives, particularly those targeting multidrug-resistant pathogens, and oncology.

The company possesses a robust pipeline of drug candidates and has successfully advanced several products through various stages of clinical development. Their comprehensive operations include drug discovery, preclinical studies, clinical trials, and the eventual production and marketing of their pharmaceutical products. This integrated approach highlights their role as a developer and manufacturer of proprietary pharmaceutical solutions.

TAIGEN BIOTECHNOLOGY CO.,LTD from Taiwan manufactures or sells the following products:

Nemonoxacin (Marketed as Taigexyn)

An innovative non-fluorinated quinolone antibiotic.

Indicated for Community-Acquired Bacterial Pneumonia (CABP).

Also being developed for Diabetic Foot Infection (DFI) and Bacteremia.

Burixafor (TG-1000)

A CXCR4 antagonist.

In Phase III clinical trials for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

TG-3000

A broad-spectrum antiviral drug.

Currently in the preclinical stage of development.